Karen Silence, PhDHead Preclinical Product Development at Argenx
I worked for four years at the university of Brussels developing the Nanobody platform which lead to the establishment of Ablynx, where I was the first employee. I was inventor and project leader for Caplacizumab, the first and only Nanobody approved today.
After that I joined argenx where I was inventor and project leader for ARGX-110, ARGX-117, ARGX-119 and ARGX-120. I work since 6 years as an independent consultant and supported argenx, Citryll, Catalym and Staten with the preclinical development of their antibodies. At this moment I am head of all late stage discovery programs at argenx as a consultant and advisor for Fair Journey Biologics.